://www.mesothelioma-health.org/images/r_2.jpg" border="0" width="569" height="20" alt="Mesothelioma Health">



Copyright 2006 Mesothelioma-Health.org
All attorney listings are a paid attorney advertisement, and do not in any way constitute a referral
or endorsement by an approved or authorized lawyer referral service.
  logger.com/css/navbar/1.css); div.b-mobile {display:none;}
Send As SMS




        


Talk to a operator live online for your free evaluation

Mesothelioma Health


Mesothelioma Health

 

Mesothelioma Health

Mesothelioma Health Information

Drug company gets $40M in venture funds

The company's Morab-009 compound is in early stage testing at Fox Chase Cancer Center in Philadelphia, Johns Hopkins in Baltimore and the National Cancer Institute in patients with pancreatic, mesothelioma, non-small cell lung and ovarian cancer.

October 12, 2006 01:51 PM ET

Morphotek Inc. said Thursday it raised $40 million through a private stock sale to a group of venture capital firms.

The proceeds will be used by the Exton, Pa., biopharmaceutical company to advance its lead therapeutic antibodies, Morab-003 and Morab-009, and its own experimental compounds which are all being studied as potential treatments of oncology, inflammatory and infectious diseases.

Morphotek's lead antibody, Morab-003, targets a surface receptor on cancer cells known as folate receptor alpha that are found on ovarian, breast, colorectal, lung and renal tumors.

The company's Morab-009 compound is in early stage testing at Fox Chase Cancer Center in Philadelphia, Johns Hopkins in Baltimore and the National Cancer Institute in patients with pancreatic, mesothelioma, non-small cell lung and ovarian cancer... (Read More)


 


Mesothelioma Health



Copyright 2006 Mesothelioma-Health.org
All attorney listings are a paid attorney advertisement, and do not in any way constitute a referral
or endorsement by an approved or authorized lawyer referral service.